Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insight, 2022
This report can be delivered to the clients within 2-3 working days
DelveInsight’s, “Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insight, 2022” report provides comprehensive insights about 13+ companies and 13+ pipeline drugs in Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021: Overview
?-syn is an abundant 14 kDa protein consisting of 140 amino acids and comprised of three domains: an N-terminal lipid-binding alpha-helix; a non-amyloid-component (NAC); and an acidic C-terminal tail. The N-terminal domain of ?-syn is characterized by a series of seven 11-residue imperfect repeats, each based upon a highly conserved KTKEGV hexameric motif that is also observed in the ?-helical domain of apolipoproteins. Parkinson’s disease (PD) is one of the most common neurodegenerative disorders with a global burden of approximately 6.1 million patients. Alpha-synuclein has been linked to both the sporadic and familial forms of the disease. Moreover, alpha-synuclein is present in Lewy-bodies, the neuropathological hallmark of PD, and the protein and its aggregation have been widely linked to neurotoxic pathways that ultimately lead to neurodegeneration. Such pathways include autophagy/lysosomal dysregulation, synaptic dysfunction, mitochondrial disruption, and endoplasmic reticulum (ER) and oxidative stress. Alpha-synuclein has not only been shown to alter cellular pathways but also to spread between cells, causing aggregation in host cells. Therapeutic approaches will need to address several, if not all, of these angles of alpha-synuclein toxicity.
'Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insight, 2022' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 pipeline landscape is provided which includes the disease overview and Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 treatment guidelines. The assessment part of the report embraces, in depth Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 Emerging Drugs
Further product details are provided in the report……..
Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021: Therapeutic Assessment
This segment of the report provides insights about the different Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 drugs segregated based on following parameters that define the scope of the report, such as:
Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 drugs.
Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insight, 2022” report provides comprehensive insights about 13+ companies and 13+ pipeline drugs in Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021: Overview
?-syn is an abundant 14 kDa protein consisting of 140 amino acids and comprised of three domains: an N-terminal lipid-binding alpha-helix; a non-amyloid-component (NAC); and an acidic C-terminal tail. The N-terminal domain of ?-syn is characterized by a series of seven 11-residue imperfect repeats, each based upon a highly conserved KTKEGV hexameric motif that is also observed in the ?-helical domain of apolipoproteins. Parkinson’s disease (PD) is one of the most common neurodegenerative disorders with a global burden of approximately 6.1 million patients. Alpha-synuclein has been linked to both the sporadic and familial forms of the disease. Moreover, alpha-synuclein is present in Lewy-bodies, the neuropathological hallmark of PD, and the protein and its aggregation have been widely linked to neurotoxic pathways that ultimately lead to neurodegeneration. Such pathways include autophagy/lysosomal dysregulation, synaptic dysfunction, mitochondrial disruption, and endoplasmic reticulum (ER) and oxidative stress. Alpha-synuclein has not only been shown to alter cellular pathways but also to spread between cells, causing aggregation in host cells. Therapeutic approaches will need to address several, if not all, of these angles of alpha-synuclein toxicity.
'Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insight, 2022' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 pipeline landscape is provided which includes the disease overview and Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 treatment guidelines. The assessment part of the report embraces, in depth Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 R&D. The therapies under development are focused on novel approaches to treat/improve Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021.
This segment of the Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 Emerging Drugs
- UCB0599: UCB Biopharma
- Prasinezumab: Prothena Corporation/Roche
Further product details are provided in the report……..
Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021: Therapeutic Assessment
This segment of the report provides insights about the different Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 drugs.
Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 Report Insights
- Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 drugs?
- How many Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 and their status?
- What are the key designations that have been granted to the emerging drugs?
- UCB Biopharma
- Lundbeck A/S
- Enterin
- Ionis Pharmaceuticals
- Abbvie
- Denali Therapeutics
- UCB0599
- Lu AF82422
- ENT-01
- ION-464
- ABBV-0805
- ATV:?Syn
Introduction
Executive Summary
Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
• Comparative Analysis
Drug Name: Company Name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
UCB0599: UCB Biopharma
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early stage products (Phase I)
• Comparative Analysis
Lu AF82422: Lundbeck A/S
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Preclinical stage products
• Comparative Analysis
Drug Name: Company Name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 Key Companies
Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 Key Products
Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021- Unmet Needs
Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021- Market Drivers and Barriers
Appendix
Executive Summary
Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
• Comparative Analysis
Drug Name: Company Name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
UCB0599: UCB Biopharma
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early stage products (Phase I)
• Comparative Analysis
Lu AF82422: Lundbeck A/S
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Preclinical stage products
• Comparative Analysis
Drug Name: Company Name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 Key Companies
Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 Key Products
Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021- Unmet Needs
Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021- Market Drivers and Barriers
Appendix
LIST OF TABLES
Table 1 Total Products for Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
